Home > Insider Trading > Filing (0000950170-25-003490)

Filing Details

Accession Number:: 0000950170-25-003490
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-01-08 16:50:29
Reporting Period:: 2025-01-06

Accepted Time:: 2025-01-08 16:50:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1861560	Nuvalent Inc.	NUVL	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1862146	Durant Christopher Turner	C/O Nuvalent, Inc. One Broadway, 14Th Floor Cambridge MA 02142	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Acquisiton	2025-01-06	18,750	$0.00	66,563	No	4	A	Direct
Class A Common Stock	Disposition	2025-01-06	1,152	$78.28	65,411	No	4	S	Direct
Class A Common Stock	Disposition	2025-01-06	691	$79.33	64,720	No	4	S	Direct
Class A Common Stock	Disposition	2025-01-06	2,173	$80.54	62,547	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Class A Common Stock	Stock Option (Right to Buy)	Acquisiton	2025-01-06	37,500	$0.00	37,500	$78.09

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
37,500		2035-01-06	No	4	A	Direct

Footnotes

Consists of shares of Nuvalent, Inc. Class A Common Stock issuable under restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Nuvalent, Inc. Class A Common Stock. The RSUs vest in three equal annual installments following January 6, 2025, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
The sale was effected pursuant to a durable Rule 10b5-1 sell-to-cover instruction letter entered into on December 6, 2023 to satisfy the reporting person's tax withholding obligations upon the vesting of previously granted equity awards.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.02 to $79.01, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (5) of this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.02 to $79.97, inclusive.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.04 to $81.03, inclusive.
The shares underlying this option vest over the four years following January 6, 2025 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.